Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model

Journal of Clinical Investigation

Volumn 112, Issue 10, 2003, Pages 1581-1588

  Neff, Tobias ^a   Horn, Peter A ^a,e   Peterson, Laura J ^a   Thomasson, Bobbie M ^a   Thompson, Jesse ^a   Williams, David A ^b   Schmidt, Manfred ^c   Georges, George E ^a,d   Von Kalle, Christof ^b   Kiem, Hans Peter ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOTOXIC AGENT; GENE PRODUCT; METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CELL POPULATION; CELL PROTECTION; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; DNA REPAIR; DOG; GENE THERAPY; GRANULOCYTE; MOLECULAR CLONING; NONHUMAN; ONCORETROVIRUS VECTOR; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CARMUSTINE; CELL LINEAGE; DOGS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, ANIMAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 0347086142     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318782     Document Type: Article

References (37)

1. Cavazzana-Calvo, M., et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:669-672.
2. Hacein-Bey-Abina, S., et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:1185-1193.
3. Aiuti, A., et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2410-2413.
4. Williams, D.A., and Smith, F.O. 2000. Progress in the use of gene transfer methods to treat genetic blood diseases. Hum. Gene Ther. 11:2059-2066.
5. Kurre, P., and Kiem, H.P. 2000. Progress towards hematopoietic stem cell gene therapy. Curr. Opin. Mol. Ther. 2:400-411.
6. Noguchi, P. 2003. Risks and benefits of gene therapy. N. Engl. J. Med. 348:193-194.
7. Hanenberg, H., et al. 1996. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2:876-882.
8. Kiem, H.P., et al. 1998. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 92:1878-1886.
9. Tisdale, J.F., et al. 1998. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 92:1131-1141.
10. Goerner, M., et al. 1999. The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs. Blood. 94:2287-2292.
11. Kiem, H.P., et al. 1999. Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector. Gene Ther. 6:966-972.
12. Kelly, P.F., Vandergriff, J., Narhwani, A., Nienhuis, A.W., and Vanin, E.F. 2000. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood. 96:1206-1214.
13. Goerner, M., et al. 2001. Sustained multilineage gene persistence and expression in dogs transplanted with CD34 marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood. 98:2065-2070.
14. Horn, P.A., Topp, M.S., Morris, J.C., Riddell, S.R., and Kiem, H.P. 2002. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-psoudotype oncoretroviral vectors produced by human packaging cells. Blood 100:3960-3967.
15. Huhn, R.D., et al. 1999. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum. Gene Ther. 10:1783-1790.
16. Neff, T., and Blau, C.A. 2001. Pharmacologically regulated cell therapy. Blood. 97:2535-2540.
17. Neff, T., et al. 2002. Pharmacologically regulated in vivo selection in a large animal. Blood. 100:2026-2031.
18. Sorrentino, B.P. 2002. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer. 2:431-441.
19. Ragg, S., et al. 2000. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60:5187-5195.
20. 6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood. 95:3078-3084.
21. Persons, D.A., et al. 2003. Successful treatment of murine β-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood. 102:506-513.
22. Maris, M., and Storb, R. 2002. Outpatient allografting in hematologic malignancies and nonmalignant disorders: applying lessons learned in the canine model to humans. In Non-myeloablative allogeneic transplantation. A. Bashey and E.D. Ball, editors. Kluwer Academic Publishers. Boston, Massachusetts, USA. 149-175.
23. Wagner, J.L., Works, J.D., and Storb, R. 1998. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens. 52:397-401.
24. Storb, R., et al. 1997. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054.
25. McSweeney, P.A., et al. 1998. Characterization of monoclonal antibodies that recognize canine CD34. Blood. 91:1977-1986.
26. Williams, D.A., et al. 2000. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 96:1646-1654.
27. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
28. Horn, P.A., et al. 2002. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther 9:1464-1471.
29. Georges, G.E., et al. 2000. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood. 95:3262-3269.
30. + cells from the cord blood of ADA-deficient SCID neonates. Nat. Med. 9:463-468.
31. Schmidt, M., et al. 2002. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 100:2737-2743.
32. Abonour, R., et al. 2000. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6:652-658.
33. Stadtmauer, E.A., et al. 2000. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 342:1069-1076.
34. Citron, M.L., et al. 2003. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21:1431-1439.
35. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20:2277-2283.
36. Rappa, G., Lorico, A., Hildinger, M., Fodstad, O., and Baum, C. 2001. Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. Hum. Gene Ther. 12:1785-1796.
37. Seiter, K., et al. 2002. Phase I study of temozolomide in relapsed/refractory acute leukemia. J. Clin. Oncol. 20:3249-3253.